Figure 2.

Intraperitoneal (i.p.) injection of transactivator of transcription (TAT)-Ngn2 improved cognitive functional recovery. (A) The delivery and distribution of TAT-Ngn2 fusion proteins in the hippocampus. Double immunofluorescence histochemical staining was performed at 6 h and 48 h after i.p. administration of TAT-Ngn2 (250 mg/kg; n = 6 for each group). Scale bar = 50 μm. (B) Total motor scores (TMSs) were recorded in each animal at 48 h after reperfusion (n = 8 for each group, nine serial sections were acquired per mouse in the same area, serial five sections in the middle of nine serial sections were observed and analyzed per animal). (C) The latency in the step-down passive avoidance test was measured in each animal at 24 h after reperfusion (n = 8 for each group). (D) The number of errors in the step-down passive avoidance test was measured in each animal at 48 h after reperfusion (n = 8 for each group). (E) Mean trials to the first avoidance response on the T-maze were measured in each animal at 48 h after reperfusion (n = 8 for each group). (F) Mean trials to criterion on the T-maze were measured in each animal at 48 h after reperfusion (n = 8 for each group). (G) The transfer latency (TL) on the elevated plus maze was measured in each animal at 48 h after reperfusion (n = 8 for each group; *P < 0.05 vs. the sham group, ^#P < 0.05 vs. the bilateral common carotid artery occlusion (BCCAO) group). The data from the behavioral experiments were analyzed by one-way analysis of variance followed by Tukey’s multiple comparison tests.